CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Cleocin Phosphate In Dextrose 5% In Plastic Container patents expire, and what generic alternatives are available?

Cleocin Phosphate In Dextrose 5% In Plastic Container is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cleocin Phosphate In Dextrose 5% In Plastic Container

A generic version of CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as clindamycin phosphate by HIKMA on April 25^th, 1988.

Summary for CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	050639-001	Aug 30, 1989		DISCN	Yes	No
Pfizer	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	050639-002	Aug 30, 1989		DISCN	Yes	No
Pfizer	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER	clindamycin phosphate	INJECTABLE;INJECTION	050639-003	Apr 10, 1991		DISCN	Yes	No

Summary
Clecocin Phosphate in Dextrose 5% in a plastic container is an intravenous antibiotic formulation containing cleocin phosphate (clindamycin phosphate). Its market viability depends on factors such as therapeutic demand, competitive landscape, patent status, manufacturing complexity, and regulatory environment. The drug primarily targets bacterial infections susceptible to clindamycin, including skin, respiratory, and intra-abdominal infections. Investment considerations include patent expiry timelines, product differentiation options, manufacturing scalability, and evolving clinical guidelines impacting antibiotic use.

---

What Is the Market Position and Therapeutic Demand?
Clecocin Phosphate (clindamycin phosphate) is frequently prescribed for anaerobic infections and certain Gram-positive bacterial infections. The intravenous formulation in dextrose 5% (D5%) targets hospital use, especially for invasive or severe infections where oral therapy is inadequate.
Market demand hinges on the prevalence of bacterial infections, hospital infection rates, and antimicrobial stewardship policies affecting outpatient vs. inpatient antibiotic use.
In 2022, the global antibiotics market reached approximately $49 billion, with hospitals accounting for just over 60% of sales. The hospital IV segment, including formulations like Cleocin Phosphate, has steady demand driven by acute care settings.
Therapeutic Niches:

• Skin and soft tissue infections
• Respiratory tract infections
• Gynecological infections
• Intra-abdominal infections

Analysis suggests consistent need in hospital settings, with growth potential tied to infection management protocols and antimicrobial resistance trends.

---

What Are Competitive and Patent Considerations?
Clecocin Phosphate in Dextrose 5% typically has longstanding market presence, with many formulations established and patent protections expiring or to expire shortly.

• Original patents on clindamycin formulations largely expired by early 2010s, opening generic manufacturing avenues.
• Market share is heavily contested among generics, with key players including Mylan, Teva, Sandoz, and Hikma.
• Patent exclusivities for any novel formulation or delivery method could extend market exclusivity, encouraging investment in reformulations or new delivery systems.

Potential barriers include:

• Ubiquity of generic alternatives, constraining margins.
• Price competition among generics.
• Limited patent protection for current formulations.

Investment appeal is higher if the company can develop proprietary formulations or delivery systems that improve stability, dosing, or reduce side effects.

---

What Are Manufacturing and Regulatory Risks?

• Manufacturing of IV drugs requiring sterile conditions involves complex quality control processes. Scaling production needs compliance with Good Manufacturing Practices (GMP) and may face supply chain disruptions.
• Regulatory approval for generic versions depends on demonstrating bioequivalence and safety.
• New formulations or delivery methods may require extensive clinical testing and regulatory review, raising costs and delays.

In recent years, increased regulatory scrutiny on sterility and manufacturing quality has elevated compliance costs but also created higher barriers for substandard manufacturers.

---

Financial and Investment Indicators

• Pricing: IV antibiotics such as cleocin phosphate are priced higher than oral versions, but premiums are subject to hospital negotiations and insurance coverage.
• Market Penetration: Widely used but limited growth unless new indications or formulations develop.
• R&D Expenses: Developing new formulations requires significant investment, with timeframes of 3-5 years for approval.
• Margins: Generic IV antibiotics tend to have lower margins due to high competition but can generate steady cash flows if manufacturing costs are optimized.

Establishing a differentiated product, such as a formulation with extended stability or reduced infusion time, can provide competitive advantages.

---

Regulatory Environment and Policy Trends

• Antibiotic stewardship programs aim to limit overuse, potentially reducing prescriptions of broad-spectrum antibiotics like clindamycin.
• Growing resistance may shift prescribing patterns or expand indications, impacting demand.
• FDA and EMA focus on manufacturing standards, safety, and efficacy for IV antibiotics and generic drugs.
• Recent policies incentivize development of antibiotics with novel mechanisms or formulations to combat resistance, but cleocin phosphate's status is largely mature and non-exclusive.

Investment strategies should monitor policy shifts favoring innovative formulations or new indications.

---

Key Takeaways

• Cleocin Phosphate in Dextrose 5% has stable hospital-based demand but faces intense generic competition.
• Market expansion is limited without product differentiation or novel indications.
• Patent expiries for original formulations facilitate generic entry, pressuring margins.
• Manufacturing complexity and regulatory requirements pose both risks and barriers.
• Strategic investments could focus on reformulations or combination therapies with competitive advantages.

---

FAQs

Last updated: February 4, 2026

1. Are there opportunities for developing branded formulations?
   Yes. Reformulating cleocin phosphate with improved stability or dosing convenience can create a competitive niche.

2. What is the current patent situation?
   Most original patents related to formulations expired by the early 2010s, leading to widespread generic availability.

3. How does resistance impact future demand?
   Rising resistance necessitates alternative antibiotics, potentially reducing clindamycin's use unless new indications emerge.

4. What are the key regulatory hurdles?
   Bioequivalence studies, sterile manufacturing compliance, and quality controls are primary hurdles for generics or new formulations.

5. Is there growth potential outside hospital settings?
   Limited; the drug is primarily used intravenously in hospitals, with outpatient use restricted to oral formulations.

---

References
[1] MarketWatch. "Global antibiotics market size." 2022.
[2] FDA. "Guidance for Industry: Bioavailability and Bioequivalence Studies." 2022.
[3] IQVIA. "Hospital antibiotic consumption data." 2022.